The legal landscape surrounding cannabis has been quite fluid for the past few years. The 2014 Farm Bill launched pilot programs for hemp, and the 2018 Farm Bill made it legal for farmers in all states and tribes to grow industrial hemp under state and tribal programs. The legislation classified hemp as cannabis with less than 0.3% THC (delta-9 tetrahydrocannabinol).
THC is the chemical responsible for marijuana’s infamous high, but hemp produces this chemical at reduced levels. Due to this, hemp and its extracts won’t give you a psychoactive high.
The hemp and CBD sector quickly flourished once industrial hemp became legal, but the industry was barely regulated and it was hurting the farmers and consumers. Enter October 2019, and the U.S. Department of Agriculture published the interim final rule on hemp, finally giving the sector a more comprehensive regulatory structure.
The state of Tennessee is among the states still trying to work out how to integrate cannabis products into the market. Senator Kerry Roberts recently released a Legislative Survey asking citizens to offer their opinions on legalizing CBD with higher levels of THC or marijuana. The survey says;
“Cannabis oils (CBD) are legal in Tennessee. CBD oils generally contain only trace amounts of THC, the chemical that creates the high in marijuana, but some advocates want to legalize CBD or marijuana with THC for pain relief or other benefits. Should Tennessee legalize ‘medical’ CBD or marijuana with higher amounts of THC to be dispensed under a doctor’s supervision?”
According to anecdotal evidence, CBD is packed with potent medicinal properties, and it is capable of managing the symptoms of conditions such as anxiety, insomnia, high blood pressure, and chronic pain. Though there have been a few studies looking into these claims, most of the therapeutic claims are unproven, and the FDA has forbidden companies from advertising CBD products as medicinal products.
The only researched and clinically tried medical benefit concerns seizures. In June 2018, the FDA approved a CBD-based drug called Epidiolex to manage seizures in two rare and hard to treat pediatric epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome.
The senator told local media outlets that it is essential for him to know the options and postings of his constituents on the issue. “This year’s survey covers a variety of topics and only takes a couple of minutes to complete. With the response I’m receiving. I should have a good idea of where Robertson County folks stand on the issues. I look forward to sharing the results after people have a chance to respond.”
Industry watchers think that companies, such as HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF), linked to the cannabidiol industry would love to see all lawmakers taking the pulse of their voters and then making decisions that reflect the wishes of those voters.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
